Dr. Ko Un “Clara” Park and Dr. Mylin Torres present the latest evidence-based changes to the SLNB in early-stage breast cancer guideline. They discuss the practice-changing trials that led to the ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...

Fig 1. Summary of key recommendations. ALN, axillary lymph node; ALND, axillary lymph node dissection; CDK, cyclin-dependent kinase; cm, centimeter; H, high; HER2 ...

SAN ANTONIO -- Patients with early breast cancer who skipped axillary lymph node dissection (ALND) lived just as long as those who underwent sentinel lymph node biopsy (SLNB), the randomized INSEMA ...

Omitting SLNB in older patients with early-stage, HR-positive, HER2-negative breast cancer showed similar safety and efficacy to performing the procedure. The BOOG 13-08 trial demonstrated comparable ...

The Melanoma Institute of Australia (MIA) previously developed a risk calculator for sentinel lymph node (SLN) metastasis risk to help clinicians and patients with primary cutaneous melanoma decide ...

To investigate this further, first author, Gabriella N. Tortorello, MD, and a research team from the University of Pennsylvania, performed a retrospective cohort study with data from the National ...